All Bioinformatics articles – Page 3
-
ArticleAgentic AI: teaching machines to think like scientists
What happens when AI stops guessing and starts reasoning? Agentic AI is bringing scientific logic into the heart of drug discovery.
-
ArticleThe data fragmentation problem holding drug discovery back
The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of Product at Certara, explains how better infrastructure and AI can help teams work faster and make decisions with more confidence.
-
NewsNew AI model links genetic mutations to specific diseases
Scientists have developed a new artificial intelligence tool that can identify harmful genetic mutations and predict the types of diseases they are likely to cause, offering faster diagnosis and new opportunities for drug discovery.
-
NewsNew beta lab platform to streamline early-stage research
UK life science software company Lab Thread has launched the beta of its unified lab platform, designed to streamline research workflows.
-
NewsLife sciences face ‘scientific content crisis’ in AI adoption
A new survey by the Pistoia Alliance reveals a growing ‘scientific content crisis’ in life sciences, showing that incomplete data and weak governance are limiting the accuracy and adoption of AI in research and development.
-
ArticleRVX-001: a universal vaccine to tackle antimicrobial resistance
Drug-resistant infections are on the rise, endangering global health. Neil Murray from ReNewVax explains how the company’s universal pneumococcal vaccine, RVX-001, could reduce antibiotic use and help curb antimicrobial resistance.
-
ArticleMaking science run at the speed of thought: the reality of AI in drug discovery – Part 1
Everyone talks about AI speeding up drug discovery, but Eric Ma explains why, without clean data and statistical discipline, it can actually do the opposite.
-
NewsZuckerberg's Biohub announces AI-powered biology to accelerate drug discovery
The initiative combines cutting-edge artificial intelligence with large-scale biological data, with the aim to transform how new treatments, drugs and therapies are developed.
-
ArticleInside ELRIG Drug Discovery 2025: automation, AI and human-relevant models
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
-
NewsHow AI and cell data combine to make drug discovery faster
Cellarity has published a new paper in detailing an AI-powered framework that integrates single-cell transcriptomics to make drug discovery faster and more successful.
-
NewsCloneSeq-SV: new blood test tracks ovarian cancer recurrence
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
-
ArticleBeyond templates: advancing protein–protein interaction structure prediction with AI
Dr Alan Nafiiev evaluates template-based, docking and template-free approaches to PPI prediction, highlighting how AI can enhance structural accuracy.
-
ArticleMaking sense of AI: bias, trust and transparency in pharma R&D
AI is increasingly used in drug discovery, but hidden bias and ‘black box’ models threaten trust and transparency. This article explores how explainable AI can turn opaque predictions into clear, accountable insights.
-
ArticleBeyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 3
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
-
ArticleWhat if drug discovery took months, not decades?
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 3
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 2
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 2, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 1
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
-
ArticleWhat single cells are revealing about brain disorders
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
-
ArticleMachine Learning and AI in Enhancing Image Analysis of 3D Samples
Want to understand the real impact of AI in 3D sample analysis? This episode cuts straight to how machine learning is accelerating research and overcoming current limitations.